1995.09 - 1999.06 ，华中农业大学， 畜牧兽医专业毕业，农学学士 2000.09－2005.06， 华中农业大学， 预防兽医学专业毕业，农学博士

2012.12 – 至今，华中农业大学，动物科技学院-动物医学院预防兽医学系，教授、博士生导师2011.08 – 2012.08 , 美国弗罗里达国际大学，生物化学系，博士后研究2008.01 -2012.12，华中农业大学, 动物科技学院-动物医学院预防兽医学系，副教授、硕士生导师2005.07 – 2007.12 , 华中农业大学, 动物科技学院-动物医学院预防兽医学系，讲师​

​A著作类 1. 《兽医实验室诊断》、《兽医手册》、《基因组学》等参编著作3部。 B论文类（第一或通讯作者38篇） 1. Binding of Fibronectin to SsPepO Facilitates the Development of Streptococcus suis Meningitis. 2017.12 2. The manganese efflux system MntE contributes to the virulence of Streptococcus suis serotype 2. Microb Pathog. 2017 Sep;110:23-30. 3. Identification of four type II toxin-antitoxin systems in Actinobacillus pleuropneumoniae. FEMS Microbiol Lett. 2017 Jul 3;364(12 4. The 1910HK/RR two-component system is essential for the virulence of Streptococcus suis serotype 2. Microb Pathog. 2017 Mar;104:137-145 5. The formate-tetrahydrofolate ligase is involved in virulence of Streptococcus suis serotype 2. Microbial Pathogenesis , 2016, 98: 149-154 6. Contribution of NADH oxidase to oxidative stress tolerance and virulence of Streptococcus suis serotype 2. VIRULENCE, 2016, 17:1-13 7. The CodY regulator is essential for virulence in Streptococcus suis serotype 2. Sci Rep, 2016, 6：21241-21241. 8. Identification and characterization of the chromosomal yefM-yoeB toxin-antitoxin system of Streptococcus suis, Sci Rep. 2015, 5：13125-13125. 9. Evaluation of the protective efcacy of four novel identiedmembrane associated proteins of Streptococcus suis serotype 2. Vaccine, 2015, 33: 2254-2260. 10. Actinobacillus pleuropneumoniae two-component system QseB/QseC regulates the transcription of PilM, an important determinant of bacterial adherence and virulence. Veterinary Microbiology, 2015, 177（1-2）：184-192. 11. Construction, characterization and evaluation of protection efficacy of streptococcus suis double mutant strain ΔSsPep/ΔSsPspC as a live vaccine candidate in mice. Microbiological Research, 2015, 170: 87-94. 12. Deletion of the znuA virulence factor attenuates Actinobacillus pleuropneumoniae and confers protection against homologous or heterologous strain challenge. Veterinary Microbiology, 2014, 174（3-4）: 531-539. 13. Two Spx Regulators Modulate Stress Tolerance and Virulence in Streptococcus suis Serotype 2. Plos one, 2014, 9（9）：108197. 14. The live attenuated Actinobacillus pleuropneumoniae triple-deletion mutant ΔApxICΔApxIICΔApxIV--ORF1 strain SLW05 immunizes pigs against lethal challenge with Haemophilus parasuis. Clin Vaccine Immunol, 2013, 2(20): 134-139. 15. Immunogenicity and protective efficacy of recombinant Haemophilus parasuis SH0165 putative outer membrane proteins, Vaccine, 2013, 31（2）: 347-353. 16. Monoclonal Antibodies Against Actinobacillus pleuropneumoniae TonB2 Protein Expressedin Escherichia coli, HYBRIDOMA, 2012, 31（5）：347-351. 17. Construction and immune effect of Haemophilus parasuis DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in mice. Vaccine, 2012, 30（48）：6839-6844. 18. Evaluation of recombinant proteins of Haemophilus parasuis strain SH0165 as vaccine candidates in a mouse model. Research in Veterinary Science, 2012, 93（1）：51-56. 19. Cloning, expression and characterization of a cell wall surface protein, 6-phosphogluconate dehydrogenase of Haemophilus parasuis. Research in Veterinary Science, 2012, 93（1）：57-62. 20. Cloning, expression, and characterization of TonB2 from Actinobacillus pleuropneumoniae and potential use as an antigenic vaccine candidate and diagnostic marker. Canadian Journal of Veterinary Research, 2011, 75（3）：183-190. 21. Influences of ORF1 on the Virulence and Immunogenicity of Actinobacillus pleuropneumoniae. Current Microbiology, 2011, 63（6）：574-580. 22. SsPep contributes to the virulence of Streptococcus suis. Microbial Pathogenesis, 2011, 51（5）：319-324. 23. Evaluation of the immunogenicity and the protective efficacy of a novel identified immunogenic protein, SsPepO,of Streptococcus suis serotype 2. Vaccine, 2011, 29（38）：6514-6519. 24. Genomic Characterization of Haemophilus parasuis SH0165, a Highly Virulent Strain of Serovar 5 Prevalent in China. PLos One, 2011, 6（5）：1-11. 25. The two-component regulatory system CiaRH contributes to the virulence of Streptococcus suis 2. Veterinary Microbiology, 2011, 148（1）：99-104. 26. Identification of a novel angiogenin inhibitor 1 and its association with hyaluronidase of Streptococcus suis 2. Microb Pathog, 2010, 49（1-2）：32-37. 27. Vaccination with Streptococcus suis serotype 2 recombinant 6PGD protein provides protection against S-suis infection in swine. FEMS Microbiology Letters, 2009, 296（1）：78-83. 28. Huanchun Chen. Contribution of glutamine synthetase to the virulence of Streptococcus suis serotype 2. Veterinary Microbiology, 2009, 139（1-2）：80-88. 29. In vivo induced RTX toxin ApxIVA is essential for the full virulence of Actinobacillus pleuropneumoniae. Veterinary Microbiology, 2009, 137（3-4）：282-289. 30. The orphan response regulator RevSC21 controls the attachment of Streptococcus suis serotype-2 to human laryngeal epithelial cells and the expression of virulence genes. FEMS Microbiology Letters, 2009, 292（2）：170-181. 31. Complete Genome Sequence of Haemophilus parasuis SH0165. Journal of Bacteriology, 2009, 191（4）：1359-1360. 32. Characterization of ISApl1, an insertion element identified from Actinobacillus pleuropneumoniae field isolate in China. Veterinary Microbiology, 2008, 132（3-4）：348-354. 33. Cloning, expression and characterization of a cell wall surface protein, 6-phosphogluconate-dehydrogenase, of Streptococcus suis serotype 2. Veterinary Microbiology, 2008, 130（3-4）：363-370. 34. The key virulence-associated genes of Streptococcus suis type 2 are upregulated and differentially expressed in vivo. FEMS Microbiology Letters, 2008, 278（1）：108-114. 35. Potential use an Actinobacillus pleuropneumoniae double mutant strain Delta apxIIC Delta apxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine, 2007, 25（44）：7696-7705. 36. Construction and immunogencity of a DapxIC/DapxIIC double mutant of Actinobacillus pleuropneumoniae serovar1. FEMS Microbiology Letters, 2007, 274（1）：55-62. 37. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs. Veterinary Microbiology，2007, 125（1-2）; 120-127。 38. Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker. FEMS Microbiology Letters，2005，243（1）：21-27 39. 专利“一种不含抗性标记的猪胸膜肺炎放线杆菌血清1型双基因缺失突变株的疫苗及应用”2009（第一完成） 40. 专利“区分疫苗免疫和野毒感染动物的猪胸膜肺炎放线杆菌血清7型双基因缺失突变株的疫苗及应用”2011（第一完成）